[NSAIDs for therapy of rheumatoid arthritis. Introduction].
Takasaki
Yoshinari
Y
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000008:administration & dosage; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D004304:Dosage Forms; D004359:Drug Therapy, Combination; D006801:Humans; D008565:Membrane Proteins; D010437:Peptic Ulcer / Q000139:chemically induced* / Q000517:prevention & control; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology; D054328:Proton Pump Inhibitors; D013927:Thrombosis / Q000139:chemically induced / Q000517:prevention & control
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004304:Dosage Forms; D008565:Membrane Proteins; D054328:Proton Pump Inhibitors; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D001241:Aspirin